DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.
News|Videos|March 12, 2025
RX Review: Closing knowledge gaps in pediatric allergy management
In part 4 of this 5-part series, panelists discuss gaps in pediatric food allergy care, stressing better diagnosis, education, and management.
Advertisement
Advertisement
In this Contemporary Pediatrics and HCPLive RX Review discussion, moderator Brian Schroer, MD, speaks with Colleen Kraft, MD, and Russell Traister, MD, about the most pressing gaps in clinician knowledge surrounding management of pediatric food allergy and anaphylaxis.
Related to this article
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
Maternal high egg and peanut intake in pregnancy and lactation did not lower infant IgE-mediated egg or peanut allergy at 1 year in PrEggNut.
New ecopipam analyses show tic reduction within 8 weeks and sustained to 18 months in Tourette syndrome as the FDA weighs approval.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
A recap of the top clinical trial and pipeline data readouts affecting pediatric care during September 2026.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
A recap of the top FDA approvals/regulatory decisions/pipeline updates affecting pediatric care during September 2026.
Advertisement
Advertisement